Sutro Biopharma, Inc.
STRO
$30.52
$0.973.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 99.61M | 102.48M | 105.65M | 104.47M | 66.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.61M | 102.48M | 105.65M | 104.47M | 66.43M |
| Cost of Revenue | 115.62M | 117.10M | 151.50M | 173.75M | 197.45M |
| Gross Profit | -16.01M | -14.62M | -45.85M | -69.28M | -131.02M |
| SG&A Expenses | 35.33M | 41.02M | 41.39M | 46.98M | 49.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 186.70M | 207.44M | 242.20M | 270.04M | 295.77M |
| Operating Income | -87.10M | -104.95M | -136.55M | -165.57M | -229.33M |
| Income Before Tax | -153.72M | -191.18M | -214.42M | -206.35M | -242.85M |
| Income Tax Expenses | -115.00K | -93.00K | 2.34M | 2.34M | 2.37M |
| Earnings from Continuing Operations | -153.60 | -191.09 | -216.77 | -208.70 | -245.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.60M | -191.09M | -216.77M | -208.70M | -245.22M |
| EBIT | -87.10M | -104.95M | -136.55M | -165.57M | -229.33M |
| EBITDA | -80.39M | -97.63M | -128.99M | -158.10M | -221.98M |
| EPS Basic | -16.35 | -22.50 | -25.70 | -24.94 | -29.50 |
| Normalized Basic EPS | -7.85 | -10.11 | -12.25 | -14.29 | -18.86 |
| EPS Diluted | -16.35 | -22.50 | -25.70 | -24.94 | -29.50 |
| Normalized Diluted EPS | -7.85 | -10.11 | -12.25 | -14.29 | -18.86 |
| Average Basic Shares Outstanding | 38.76M | 34.04M | 33.78M | 33.49M | 33.16M |
| Average Diluted Shares Outstanding | 38.76M | 34.04M | 33.78M | 33.49M | 33.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |